Advertisement
News
Advertisement

Ariad seeks fast approval of cancer drug compound

Tue, 07/31/2012 - 12:00am
Mass High Tech: The Journal of New England Technology

Just a few months after it won a key patent, Ariad Pharmaceuticals Inc. (Nasdaq: ARIA) has submitted a new drug application to the U.S. Food and Drug Administration for its investigational drug ponatinib to treat a rare form of leukemia, the company said Tuesday.

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading